Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis
Journal of the European Academy of Dermatology and Venereology | Dec 16, 2021
Most read this week
Journal of the European Academy of Dermatology and Venereology | Dec 16, 2021